Navigation Links
MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series
Date:2/13/2009

Eleven of eleven wounds healed in 6 weeks or less

PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that its MEDIHONEY Dressings were the focus of a case series on eleven non-healing venous leg ulcers. These wounds had previously failed to heal while being managed with such therapeutic modalities as multi-layered compression, silver antimicrobial dressings, antibiotic therapy, and hyperbaric oxygen. Six of the wounds completely healed within 4 weeks, and all eleven wounds healed within 6 weeks. The typical duration for wound healing studies having complete closure as the endpoint is 12 weeks. The case series, "Topical Leptospermum Honey (MEDIHONEY) in Recalcitrant Venous Leg Wounds: A Preliminary Case Series" was published in the February edition of Advances in Skin & Wound Care, a peer-reviewed and Medline-indexed journal.

Speaking about the case series, Derma Sciences' CEO Ed Quilty stated, "The body of evidence supporting the use of MEDIHONEY - particularly in non-healing venous leg ulcers - continues to grow. This case series validates the randomized controlled study published several months ago which showed that the addition of MEDIHONEY under compression helped to improve healing in these very difficult to heal leg ulcers. Leg ulcers are very burdensome for patients and their families, are painful, and recur often. With the evidence that has been accumulated for this patient population, MEDIHONEY is gaining traction on formularies as the lead dressing when wounds do not heal within 3-4 weeks of treatment with basic standard wound dressings. As was the case with the recent patient profile coming out of North Shore Long Island Jewish Hospital, these patients' quality of life can be improved tremendously if their wounds healed more quickly."

According to the authors (Tanisha Smith, DPM and Kennedy Legel, DPM of South Miami Hospital, and Jason R. Hanft, DPM, Director of Medical Education, Baptist Health South Florida), "As renewed interest in the use of sterile, medical-grade honey to achieve wound closure increases, justified by increased scientific and clinical data, the healing potential of Medihoney may serve as a pivotal clinical decision to accelerate the closure of recalcitrant wounds of the lower extremity."

The data from this case series has also been submitted and accepted for presentation at two of the major wound conferences in 2009: The Diabetic Foot Global Conference (DFCon) in Los Angeles, March 19-21, and The Wound Healing Society Annual Conference (WHS) in Dallas, April 26-29.

About venous leg ulcers

  • Venous leg ulcers are difficult to heal, and impair the quality of life of patients due to pain, reduction in daily living capabilities, and issues with odor (1)
  • Roughly 1% of the population will have a venous leg ulcer at some point in their lifetime (2)
  • The costs to treat venous leg ulcers in the US exceeds $1 billion (3)

    (1) Charles H. Venous leg ulcer pain and its characteristics. Journal of
        Tissue Viability. 2002;12(4):154-158.
    (2) Margolis D, Bilker W, Santanna J, Baumgarten M. Venous leg ulcer:
        incidence and prevalence in the elderly. J Am Acad Dermatol.
        2002;46(3):381-386.
    (3) de Araujo et al., Ann. Intern. Med. 2003;138(4):326-34.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY(TM), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from the University of Southern California in Q4 of 2007. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

    Contact:

    Derma Sciences, Inc.
    Edward J. Quilty
    Chairman and CEO
    equilty@dermasciences.com
    (609) 514-4744

    Allen & Caron Inc
    Rudy Barrio (US Investors)
    r.barrio@allencaron.com
    (212) 691-8087

    Brian Kennedy (Media)
    brian@allencaron.com
    (212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Derma Sciences MEDIHONEY(TM) Proven to Speed Healing in Stalled Leg Ulcers
2. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
3. Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures
4. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
5. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
6. Protein Shown to Play a Key Role in Normal Development of Nervous System
7. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
8. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
9. Evotecs EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
10. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
11. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone ... tool that shows how a cleanroom works. The ... discussions about science and technology. ... "As a technology company, SSF enthusiastically supports the ... help educators foster the next generation of innovators. ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... In an ... today GrassrootsHealth, a public health promotion and research organization, declared May as “National ... society, and other shifts in cultural behavior over the past several decades, Americans ...
(Date:5/4/2016)... ... May 04, 2016 , ... ProList is a set of ... . With ProList, editors can easily create lists for presentations, youtube productions, and ... bullet points. ProList is the perfect complement to presentation style videos. , ProList ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... engineer of patented products, announces the Everlasting Glove, a sports invention that aids ... Athletic and Sporting Goods Manufacturing industry is worth $9 billion," says Scott Cooper, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Cirius, ... patent for its innovative Secure Messaging platform, which includes secure, private messaging, large ... patent extends Cirius’s portfolio of patents around innovative features for securing, tracking, and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare ... today announced it has secured $9 million in Series A funding led by ... investment will be used by Somnoware to further fulfill its mission to connect, ...
Breaking Medicine News(10 mins):